Vancouver, British Columbia / April 16, 2018– Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce the appointments of Dr. John R. Garrett and Paul Woodward to its Board of Directors.

Dr. Garrett is a Principal of John Garrett & Partners with a practice focusing on early stage US and international biomedical companies as well as corporate initiatives in the domains of software, and communication companies. Since 2004, Dr. Garrett has led five startup companies in CEO/COO positions, including initiatives with partners emanating from Harvard University and Roswell Park Cancer Center.  Currently, he is co-CEO of Glycosyn, Inc., centered on treating/curing common childhood diseases, and the Executive Director of Glycosyn Health Initiatives, devoted to bringing life-saving treatments to children in the developing world.

Paul Woodward is currently President of Conation Capital Corp., and has been a frequent investor in early stage private companies. Paul is a former investment banker with over 30 years of experience in venture markets.

Allen Krantz, COO/CSO of the Company commented that “APC is extremely fortunate to have John’s highly skilled services with his great depth of business experience in growing companies, interpersonal skills, and technological grasp. Paul Woodward has been a strong supporter of APC. His extensive experience in capital markets and corporate finance will be a major asset to the Company going forward.”


Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. This type of agent is capable of greater potency, higher specificity, and lower toxicity than other therapies that can also attack healthy cells.  Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential.


Advanced Proteome Therapeutics Corporation
Allen Krantz, Ph.D.
Chief Operating and Chief Scientific Officer
Tel: 617 638 0340

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategies, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.